HUE050452T2 - Nukleáris transzport modulátorok és alkalmazásuk - Google Patents

Nukleáris transzport modulátorok és alkalmazásuk

Info

Publication number
HUE050452T2
HUE050452T2 HUE18164757A HUE18164757A HUE050452T2 HU E050452 T2 HUE050452 T2 HU E050452T2 HU E18164757 A HUE18164757 A HU E18164757A HU E18164757 A HUE18164757 A HU E18164757A HU E050452 T2 HUE050452 T2 HU E050452T2
Authority
HU
Hungary
Prior art keywords
nuclear transport
transport modulators
modulators
nuclear
transport
Prior art date
Application number
HUE18164757A
Other languages
English (en)
Hungarian (hu)
Inventor
Vincent Sandanayaka
Sharon Shechter
Sharon Shacham
Dilara Mccauley
Erkan Baloglu
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49448240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE050452(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of HUE050452T2 publication Critical patent/HUE050452T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE18164757A 2012-05-09 2013-05-09 Nukleáris transzport modulátorok és alkalmazásuk HUE050452T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644802P 2012-05-09 2012-05-09
US201361798188P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
HUE050452T2 true HUE050452T2 (hu) 2021-03-29

Family

ID=49448240

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE18164757A HUE050452T2 (hu) 2012-05-09 2013-05-09 Nukleáris transzport modulátorok és alkalmazásuk
HUE13779943A HUE040427T2 (hu) 2012-05-09 2013-05-09 Nukleáris transzportmodulátorok és felhasználásuk

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE13779943A HUE040427T2 (hu) 2012-05-09 2013-05-09 Nukleáris transzportmodulátorok és felhasználásuk

Country Status (32)

Country Link
US (10) US9096543B2 (OSRAM)
EP (3) EP3404027B1 (OSRAM)
JP (5) JP6195909B2 (OSRAM)
KR (5) KR102163377B1 (OSRAM)
CN (1) CN104428295B (OSRAM)
AU (5) AU2013259384B2 (OSRAM)
BR (1) BR112014027860B8 (OSRAM)
CA (1) CA2872190C (OSRAM)
CL (1) CL2014003054A1 (OSRAM)
CO (1) CO7190242A2 (OSRAM)
CY (2) CY1120832T1 (OSRAM)
DK (2) DK3404027T3 (OSRAM)
EA (1) EA036639B1 (OSRAM)
ES (3) ES2702279T3 (OSRAM)
GE (1) GEP20237477B (OSRAM)
HR (2) HRP20181838T1 (OSRAM)
HU (2) HUE050452T2 (OSRAM)
IN (1) IN2014DN09434A (OSRAM)
LT (2) LT3404027T (OSRAM)
ME (1) ME03795B (OSRAM)
MX (1) MX364992B (OSRAM)
NZ (1) NZ702663A (OSRAM)
PE (1) PE20150128A1 (OSRAM)
PL (2) PL3404027T3 (OSRAM)
PT (2) PT3404027T (OSRAM)
RS (2) RS58058B1 (OSRAM)
SG (1) SG11201407268SA (OSRAM)
SI (2) SI3404027T1 (OSRAM)
SM (2) SMT202000347T1 (OSRAM)
UA (2) UA124922C2 (OSRAM)
WO (1) WO2013170068A2 (OSRAM)
ZA (1) ZA202004892B (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2791914C (en) 2010-03-05 2019-01-15 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US9303000B2 (en) 2011-01-17 2016-04-05 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
KR102022715B1 (ko) 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 핵 수송 조절인자 및 이의 용도
SMT201800171T1 (it) 2011-07-29 2018-07-17 Karyopharm Therapeutics Inc Modulatori di trasporto nucleare contenenti idrazide e loro usi
MX364992B (es) 2012-05-09 2019-05-17 Biogen Ma Inc Moduladores del transporte nuclear y usos de los mismos.
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
CA2897333C (en) 2013-01-15 2021-07-06 Incyte Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
WO2014144772A1 (en) * 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
US9738624B2 (en) 2013-06-21 2017-08-22 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
CR20160135A (es) 2013-08-23 2016-08-05 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim
WO2015175326A1 (en) * 2014-05-13 2015-11-19 Illinois Tool Works Inc. Device and method for enhanced iridium gamma radiation sources
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
EP4112615A1 (en) 2014-08-15 2023-01-04 Karyopharm Therapeutics Inc. Compositions comprising one crystalline form of selinexor
KR101734529B1 (ko) 2015-05-08 2017-05-11 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US20200216906A1 (en) * 2015-08-25 2020-07-09 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
EP3423468A4 (en) * 2016-02-29 2019-10-23 Ohio State Innovation Foundation AZA PEPTIDE ALDEHYDE AND KETONE
CA3013799A1 (en) * 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Methods of modulating keap1
WO2017190087A1 (en) 2016-04-30 2017-11-02 Envision Diagnostics, Inc. Medical devices, systems, and methods for performing eye exams and eye tracking
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
RU2756512C1 (ru) 2018-01-10 2021-10-01 ЭксДабл-ЮФАРМА ЛТД. Пролекарства кетамина, его композиции и применения
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020092965A1 (en) 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
CN113365640A (zh) 2018-12-06 2021-09-07 比奥根Ma公司 引导肌萎缩侧索硬化症的治疗性干预的神经丝蛋白
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
CN109928939A (zh) * 2019-02-27 2019-06-25 上海卡洛化学有限公司 一种2,2,6,6-四甲基吗啉的制备方法
MX2021013211A (es) * 2019-05-01 2022-03-11 Karyopharm Therapeutics Inc Proceso para la preparacion de inhibidores de xpo1 y productos intermedios para su uso en la preparacion de inhibidores de xpo1.
CN111145135B (zh) * 2019-12-30 2021-08-10 腾讯科技（深圳）有限公司 一种图像去扰处理方法、装置、设备及存储介质
DE112022001910T5 (de) 2021-04-01 2024-01-25 Alps Alpine Co., Ltd. Vorrichtung zur erkennung einer betätigung
EP4326276A4 (en) * 2021-04-21 2025-07-30 Natco Pharma Ltd IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES
JP7737544B2 (ja) 2021-08-13 2025-09-10 エックスダブリューファーマ リミテッド ケタミン誘導体の医薬組成物及び経口剤形
WO2023172855A2 (en) * 2022-03-07 2023-09-14 Kaohsiung Medical University Methods for treating hepatitis b virus infection

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
AU4368996A (en) 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
CA2229617A1 (en) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation
EP1544197A1 (en) 1996-04-04 2005-06-22 Shionogi & Co., Ltd. Intermediates for cephem compounds
CN101817784B (zh) 1996-04-25 2012-02-01 日产化学工业株式会社 乙烯衍生物和含有该衍生物的杀有害生物剂
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
WO1999050264A1 (en) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
US7569724B2 (en) * 2000-09-29 2009-08-04 Topotarget Uk Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
JP3608050B2 (ja) 2001-07-24 2005-01-05 トヨタ自動車株式会社 ロールオーバ判別装置
KR20100107509A (ko) 2001-09-14 2010-10-05 9222-9129 퀘벡 인코포레이티드 히스톤 데아세틸라아제의 억제제
WO2004037248A2 (en) 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
MXPA05004505A (es) 2002-11-01 2005-07-26 Takeda Pharmaceutical Agente para prevenir o tratar la neuropatia.
US7342115B2 (en) 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
WO2004076418A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
MX2007001634A (es) 2004-08-11 2007-04-23 Kyorin Seiyaku Kk Nuevo derivado de acido amino benzoico ciclico.
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
USRE46792E1 (en) 2005-11-15 2018-04-17 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
WO2007102580A1 (ja) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. 多環式シンナミド誘導体
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
KR101507173B1 (ko) 2006-04-18 2015-03-30 닛뽕 케미파 가부시키가이샤 페록시좀 증식제 활성화 수용체 δ 의 활성화제
CN101443330B (zh) 2006-06-13 2012-12-19 上海海和药物研究开发有限公司 杂环非核苷类化合物及其制备方法、药物组合物和作为抗病毒抑制剂的用途
CN100503571C (zh) 2006-07-12 2009-06-24 中国药科大学 四氢异喹啉类衍生物、其制备方法及其医药用途
PL2054411T3 (pl) 2006-07-27 2015-02-27 Amorepacific Corp Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
TWI386405B (zh) 2006-09-05 2013-02-21 咪唑衍生物
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
JP2010519337A (ja) 2007-02-26 2010-06-03 コーサン バイオサイエンシーズ， インコーポレイテッド カルバメート化合物
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
JP2010531841A (ja) * 2007-07-04 2010-09-30 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤として有用な新規なピラゾール誘導体
JP2012532889A (ja) 2009-07-09 2012-12-20 クレッシェンド セラピューティクス、エルエルシー 創傷治療方法及び傷跡変性方法
US8518968B2 (en) * 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
CA2791914C (en) 2010-03-05 2019-01-15 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US9303000B2 (en) 2011-01-17 2016-04-05 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
SMT201800171T1 (it) 2011-07-29 2018-07-17 Karyopharm Therapeutics Inc Modulatori di trasporto nucleare contenenti idrazide e loro usi
KR102022715B1 (ko) 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 핵 수송 조절인자 및 이의 용도
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
MX364992B (es) 2012-05-09 2019-05-17 Biogen Ma Inc Moduladores del transporte nuclear y usos de los mismos.
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
US20160016916A1 (en) 2013-03-15 2016-01-21 Karyopharm Therapeutics Inc. Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
US9738624B2 (en) 2013-06-21 2017-08-22 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11567063B2 (en) 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
EP3172214B1 (en) 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
EP4112615A1 (en) 2014-08-15 2023-01-04 Karyopharm Therapeutics Inc. Compositions comprising one crystalline form of selinexor
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
WO2017118940A1 (en) 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
WO2018129227A1 (en) 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation

Also Published As

Publication number Publication date
JP2021063104A (ja) 2021-04-22
PT3404027T (pt) 2020-03-30
UA118085C2 (uk) 2018-11-26
ME03795B (me) 2021-04-20
EA036639B1 (ru) 2020-12-02
AU2019272017B2 (en) 2021-05-27
KR20200041984A (ko) 2020-04-22
AU2013259384A1 (en) 2014-12-18
LT2858991T (lt) 2018-11-26
ES2702279T3 (es) 2019-02-28
JP2015516434A (ja) 2015-06-11
US11318120B2 (en) 2022-05-03
RS58058B1 (sr) 2019-02-28
UA124922C2 (uk) 2021-12-15
HUE040427T2 (hu) 2019-03-28
HK1209420A1 (en) 2016-04-01
US9861614B2 (en) 2018-01-09
KR20200041986A (ko) 2020-04-22
EP3663291B1 (en) 2024-12-18
AU2019272017A1 (en) 2019-12-19
CL2014003054A1 (es) 2015-05-15
PT2858991T (pt) 2018-12-17
EA201492050A1 (ru) 2015-07-30
RS60424B1 (sr) 2020-07-31
GEP20237477B (en) 2023-03-27
KR102095429B1 (ko) 2020-03-31
US20210251968A1 (en) 2021-08-19
US9585874B2 (en) 2017-03-07
BR112014027860A2 (pt) 2017-06-27
HRP20200876T1 (hr) 2020-09-04
KR20150018809A (ko) 2015-02-24
SG11201407268SA (en) 2015-01-29
CA2872190A1 (en) 2013-11-14
WO2013170068A2 (en) 2013-11-14
MX2014013551A (es) 2015-01-16
ZA202004892B (en) 2023-03-29
PL2858991T3 (pl) 2019-01-31
DK3404027T3 (da) 2020-06-02
NZ702663A (en) 2017-03-31
SI2858991T1 (sl) 2018-12-31
EP2858991B1 (en) 2018-08-08
KR102165177B1 (ko) 2020-10-13
US20190008833A1 (en) 2019-01-10
SI3404027T1 (sl) 2020-08-31
CY1120832T1 (el) 2019-12-11
US20160354347A1 (en) 2016-12-08
CY1123476T1 (el) 2022-03-24
WO2013170068A3 (en) 2014-02-20
ES3016982T3 (en) 2025-05-12
CO7190242A2 (es) 2015-02-19
US10617677B2 (en) 2020-04-14
JP6195909B2 (ja) 2017-09-13
KR102223028B1 (ko) 2021-03-03
AU2021221398B2 (en) 2023-08-17
JP2020037585A (ja) 2020-03-12
US9266843B2 (en) 2016-02-23
US20200230110A1 (en) 2020-07-23
BR112014027860B8 (pt) 2024-04-30
JP6818849B2 (ja) 2021-01-20
US20200038373A1 (en) 2020-02-06
HRP20181838T1 (hr) 2018-12-28
SMT202000347T1 (it) 2020-07-08
DK2858991T3 (en) 2018-11-26
CN104428295A (zh) 2015-03-18
AU2013259384B2 (en) 2016-06-02
AU2018201012B2 (en) 2019-12-05
LT3404027T (lt) 2020-07-10
PE20150128A1 (es) 2015-02-23
SMT201800686T1 (it) 2019-01-11
US10058535B2 (en) 2018-08-28
CN104428295B (zh) 2017-08-08
US20130317031A1 (en) 2013-11-28
EP2858991A2 (en) 2015-04-15
US10925859B2 (en) 2021-02-23
US20150111893A1 (en) 2015-04-23
IN2014DN09434A (OSRAM) 2015-07-17
AU2016222459A1 (en) 2016-09-22
US9096543B2 (en) 2015-08-04
KR20200115688A (ko) 2020-10-07
US20180289675A1 (en) 2018-10-11
JP2018172444A (ja) 2018-11-08
US20170319551A1 (en) 2017-11-09
ES2794866T3 (es) 2020-11-19
AU2018201012A1 (en) 2018-03-01
US20160145246A1 (en) 2016-05-26
CA2872190C (en) 2024-06-25
EP3404027A1 (en) 2018-11-21
US10722497B2 (en) 2020-07-28
KR20200118240A (ko) 2020-10-14
BR112014027860B1 (pt) 2022-03-08
PL3404027T3 (pl) 2020-09-21
MX364992B (es) 2019-05-17
JP2018012715A (ja) 2018-01-25
US10335393B2 (en) 2019-07-02
AU2021221398A1 (en) 2021-09-16
EP3663291A1 (en) 2020-06-10
EP3404027B1 (en) 2020-03-04
KR102163377B1 (ko) 2020-10-08

Similar Documents

Publication Publication Date Title
ZA202004892B (en) Nuclear transport modulators and uses thereof
IL261612A (en) Nuclear transfer modulators and their uses
SG10201609097PA (en) Nuclear transport modulators and uses thereof
GB2509400B (en) Rigid-stem lead-in-method and system
SG11201406290QA (en) Pallet and pallet system
ZA201401223B (en) Hydrazide containing nuclear transport modulators and uses thereof
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
EP2665362A4 (en) NUCLEAR TRANSPORTER MODULATORS CONTAINING OLEFINS AND USES THEREOF
EP2934342A4 (en) DEVICES AND METHODS OF DISCECTOMY
EP2844247A4 (en) ROR MODULATORS AND ITS USES
PL2904124T3 (pl) Urządzenie manipulacyjne
EP2844259A4 (en) MMR MODULATORS AND USES THEREOF
EP2844260A4 (en) ROR MODULATORS AND ITS USES
IL233652A0 (en) Converted phenylimidazopyrazoles and their use
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
EP2874915A4 (en) MODIFYABLE CONTAINERS AND CONNECTING ELEMENTS
PL2884837T3 (pl) Usprawnienia w urządzeniach do obsługi zwierząt
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201214019D0 (en) SP4 and container